After-Final Practice at the USPTO and Reexamination Before CNIPA: A comparative guide for United States and Chinese patent practitioners
Executive Summary: This article compares after-final practice at the United States Patent and Trademark Office (USPTO) with reexamination before the China National Intellectual Property Administration (CNIPA), using each system’s familiar procedures to explain the other to U.S. and Chinese patent practitioners. A U.S. final Office action restricts further prosecution while preserving distinct routes for amendment, continued examination, and appeal; a Chinese rejection decision directs a dissatisfied applicant toward reexamination, which combines review of the refusal with limited opportunities for corrective amendment. The article examines amendment and evidence restrictions, U.S. pre-appeal brief review and Chinese interlocutory examination, responses to new grounds of rejection, and deadlines governing administrative and judicial review. It also explains the USPTO’s fiscal year 2026 interview policy and its implications for after-final interviews, while comparing U.S. continuing applications with Chinese divisional practice. The organizing principle is to compare the decision being challenged, the record the procedure permits, and the relief it can produce. Counsel should first determine whether the client needs correction of an existing rejection, examination of changed claims or evidence, or preservation of different claim coverage, and then select and sequence the locally available procedures
Introduction
A client receives adverse examination decisions in corresponding U.S. and Chinese patent applications. The claims still matter commercially, and the specification contains a useful fallback limitation. The client asks the same question in both jurisdictions: can we amend the claims, speak with the examiner, and keep the application moving? The answer depends on what decision has issued and which procedure remains available.
A final Office action from the U.S. Patent and Trademark Office (USPTO) restricts further prosecution before the examiner while leaving defined routes for amendment, continued examination, and appeal. A rejection decision from the China National Intellectual Property Administration (CNIPA) ends the ordinary examination stage and directs a dissatisfied applicant toward reexamination. Chinese reexamination reviews the refusal and also permits specified corrective amendments. That combination explains why neither a U.S. appeal nor a request for continued examination (RCE), standing alone, provides a complete analogy (35 U.S.C. §§ 132(b), 134(a); 37 C.F.R. §§ 1.113–1.116; Patent Law of the People’s Republic of China arts. 38, 41 (amended 2020); Implementing Regulations of the Patent Law rr. 65–67 (revised 2023)).
The useful unit of comparison is the decision being challenged, the record the procedure permits, and the relief it can produce. Cross-border counsel should first determine whether the client needs correction of an existing rejection, examination of changed claims or evidence, or preservation of different claim coverage. Counsel can then select the locally available procedure. This method explains both the similarities that make foreign practice understandable and the differences that make literal procedural translation unsafe.
This article addresses ordinary U.S. utility applications and Chinese invention applications under law and guidance current through September 23, 2026. Its comparisons run in both directions: familiar U.S. procedures help explain Chinese practice, while Chinese reexamination provides a useful starting point for understanding the separate functions of U.S. after-final submissions, RCEs, pre-appeal review, and appeals to the Patent Trial and Appeal Board (PTAB). Chinese “reexamination,” or fushen, concerns a refused application; it should not be confused with U.S. ex parte reexamination of an issued patent (Chinese Patent Law arts. 41, 45; 35 U.S.C. §§ 302–307). The Chinese Guidelines citations below refer to the Guidelines for Patent Examination 2023, as revised in 2025, effective Jan. 1, 2026. The consolidated text accompanies CNIPA Order No. 84.
Recognizing the decision that changes the procedure
For a U.S. practitioner, “final” describes the procedural status of an examiner’s action, not a determination by the Patent Trial and Appeal Board or a court. A second action may ordinarily be final, but a new ground of rejection generally prevents finality unless an applicable exception permits it, such as a new ground necessitated by the applicant’s amendment. A complaint that the examiner made the action final prematurely concerns procedure and is raised by petition. The contention that the claims are patentable presents a different question for appeal. Filing a petition does not itself suspend the response period (37 C.F.R. §§ 1.113, 1.181(f); USPTO, Manual of Patent Examining Procedure [hereinafter MPEP] §§ 706.07(a), (c)–(d)). Additional exceptions to the general restriction on new grounds are described in § 706.07(a).
Chinese practice starts from a different sequence. Article 37 provides an opportunity to address examination objections through observations or amendments. Article 38 authorizes rejection when the application still fails to satisfy the applicable requirements. The Guidelines require an opportunity to address the relevant grounds before rejection, but do not impose a universal U.S.-style sequence consisting of one nonfinal action followed by one final action. An examination opinion notification and a rejection decision, or bohui jueding, therefore require different instructions from foreign counsel (Chinese Patent Law arts. 37–38; CNIPA Guidelines pt. II, ch. 8, §§ 4.11, 6.1).
The translation matters immediately. U.S. counsel who receives a Chinese “rejection” should determine whether it is an examination opinion inviting a response or the rejection decision that starts the reexamination period. Chinese counsel receiving a U.S. “final rejection” should ask which claims and evidence are actually before the examiner and what response period remains. Neither label, without that procedural information, identifies the appropriate next filing.
Protecting the application while choosing a response
A U.S. final action ordinarily sets a three-month shortened statutory period. Extensions may generally be obtained under Rule 1.136(a), subject to the six-month statutory maximum. A timely after-final submission that fails to place the application in condition for allowance does not, by itself, prevent abandonment. Nor does the resulting advisory action ordinarily supply a new response period. Counsel should docket the final action’s deadline while separately evaluating whether the examiner entered the proposed amendment (35 U.S.C. § 133; 37 C.F.R. §§ 1.134–1.136; MPEP §§ 706.07(f), 714.13).
The two-month practice offers a limited timing benefit. When the first after-final reply is filed within two months of the final action and the advisory action is mailed after the original three-month period, the shortened period expires on the advisory action’s mailing date, and extension fees are calculated from that date. The six-month maximum still runs from the final action. Thus, an early submission may reduce extension fees attributable to the Office’s response time; it does not create another six months of prosecution (MPEP § 714.13, including form paragraph 7.39; see also id. § 706.07(f)).
China’s initial review deadline is different. The applicant has three months from receipt of the rejection decision to request reexamination and pay the reexamination fee. That statutory period cannot ordinarily be extended in the manner of a U.S. shortened response period. Current electronic-service rules treat service as occurring when the document enters the recipient’s recognized electronic system. The 15-day postal presumption should not automatically be added to an electronically served decision (Chinese Patent Law art. 41; Implementing Regulations rr. 4–6, 113; CNIPA Guidelines pt. IV, ch. 2, §§ 2.3, 2.5). CNIPA also distinguishes the statutory reexamination period from extendable designated periods in its public deadline guidance.
Restoration is a separate remedy. Under Rule 6, an applicant relying on “other justified reasons” for missing the reexamination-request deadline must seek restoration within two months after that deadline expires, complete the omitted steps, and satisfy the applicable requirements. The rule separately addresses force majeure. Counsel should not treat restoration as a routine additional filing period or wait for a later notice to start the special two-month clock (Implementing Regulations r. 6, paras. 1–3). The force-majeure provision has its own conditions and outer time limit.
In either jurisdiction, a conversation about a possible solution and the filing that preserves the application serve different purposes. Instructions to local counsel should identify the operative notice, service or mailing date, proposed substantive response, and fallback filing if informal efforts do not resolve the case.
Amending after rejection
U.S. after-final practice requires a distinction between submitting an amendment and securing its entry. Rule 1.116 permits specified amendments after final, including claim cancellation, compliance with previously identified formal requirements, and changes that place rejected claims in better form for appeal. Other amendments require a sufficient explanation of their necessity and why they were not presented earlier. In practice, an amendment that requires additional searching or consideration may be refused entry even though it narrows the claims and has clear disclosure support (37 C.F.R. § 1.116(b); MPEP §§ 714.12–714.13). The rule’s categories and the examiner’s entry determination must be considered separately from substantive patentability.
Suppose the claim covers a controller that authorizes an operation after verifying a credential. The specification also describes invalidating the credential after a single use. Adding that limitation may improve patentability, but the examiner may need another search to evaluate the combination. The applicant’s ability to point to original support answers the new-matter question; it does not establish a right to have the new combination examined after final. If the limitation is central to the desired patent, the cost of continued examination should be assessed directly rather than obscured by repeated submissions of essentially the same amendment.
The U.S. evidentiary record also becomes harder to change as the case advances. Rule 1.116(e) applies to affidavits and other evidence submitted after final. For evidence filed after the notice-of-appeal date but before the appeal brief, Rule 41.33(d)(1) adds an especially consequential condition: the examiner must determine that the evidence overcomes all rejections under appeal, in addition to the required explanation for its late submission. Later evidence is generally excluded unless a specified exception applies. Declarations needed to establish unexpected results or explain a technical distinction therefore should be planned before counsel commits to an appeal (37 C.F.R. §§ 1.116(e), 41.33(d); MPEP § 1206, pt. II). Filing on the notice-of-appeal date and filing after that date are not interchangeable under the rules.
Amendment opportunities contract further once the appeal brief is filed. Rule 41.33(b) generally limits amendments at that stage to cancellation that does not affect another pending claim’s scope and rewriting dependent claims in independent form. A brief cannot turn a previously unentered amendment into the operative claim set. The practitioner must know which claims were entered before explaining what the Board is being asked to review (37 C.F.R. §§ 41.30, 41.33(a)–(b), 41.37(c)(2); MPEP §§ 1204.04, 1206).
Chinese reexamination offers a different opportunity, governed by two independent limits. Article 33 supplies the original-disclosure boundary. Rule 66 requires amendments to address the defects identified in the rejection decision or reexamination notice. The applicant may therefore challenge the refusal and submit a supported amendment directed to the identified problem, without treating those objectives as mutually exclusive. Amendments may be presented with the reexamination request, in a response to a reexamination notice, or during an oral hearing, subject to the governing restrictions (Chinese Patent Law art. 33; Implementing Regulations r. 66; CNIPA Guidelines pt. IV, ch. 2, § 4.2; CNIPA, public consultation response (Apr. 17, 2026)).
That opportunity does not permit wholesale claim redesign. The Guidelines ordinarily exclude broadening relative to the rejected claims, switching to a nonunitary technical solution, changing claim type or adding claims, and amendments to claims or specification material not implicated by the rejection. For that last category, the Guidelines recognize exceptions for obvious textual errors and defects of the same nature as those identified in the rejection. These qualifications do not dispense with the other stage-specific amendment restrictions or the original-disclosure requirement (CNIPA Guidelines pt. IV, ch. 2, § 4.2, especially item (4)). CNIPA’s Apr. 17, 2026 public response reproduces these categories but also contains obsolete Rule 61 references; the operative current regulation is Rule 66.
For the controller example, U.S. counsel should ask Chinese counsel to explain how the single-use limitation cures the rejection and why its introduction is procedurally permissible. Chinese counsel handling the corresponding U.S. application should separately assess entry, evidentiary timing, and the need for an RCE. In both systems, later evidence may help establish a technical proposition, but the opportunity to submit it does not make it a substitute for missing original disclosure.
Conducting interviews under the FY2026 policy
After-final interviews remain available under the USPTO’s substantive interview standards. MPEP Section 713.09 normally permits one when the discussion can produce allowance or clarify issues for appeal with only nominal further consideration. Requests that merely repeat existing arguments, or introduce limitations requiring a new search or more than nominal reconsideration, should be denied. Further interviews may be held when the examiner believes they will expedite appeal or disposition. These standards make the proposed purpose of the conversation important before scheduling begins (37 C.F.R. § 1.133; MPEP § 713.09).
The FY2026 change concerns the time credited to examiners. The USPTO’s October 2025 presentation contrasts the prior one-hour allocation for an interview with one attribute hour per new application or RCE under the FY2026 plan. Additional interview time may be authorized by a Supervisory Patent Examiner. The May 2026 Interview Best Practices explains that the hour encompasses preparation and related tasks as well as the interview itself. It is an examination-work allocation, not a promise of a one-hour meeting or an absolute limit of one conversation (USPTO, The Role of a Patent Examiner in the IP Community, slide 25 (Oct. 15, 2025); USPTO, AIPLA & IPO, Interview Best Practices 4 (May 2026)).
The practical implication is that counsel who already used an interview during nonfinal prosecution should plan a later after-final request with the additional-time approval requirement in mind. That is a reason to identify a concrete unresolved issue and explain why the discussion can advance the case. It does not justify assuming that a second interview is categorically unavailable, and filing an RCE solely to obtain another conversation may be disproportionate when the existing record already supports appeal.
Preparation should reflect the limited time available. The May 2026 guidance recommends a focused advance agenda identifying the claims, relevant passages, and proposed amendments. For the controller example, a useful agenda would identify the single-use limitation, its support, and the precise point on which the examiner’s reaction is sought. This agenda is most useful where counsel has a concrete basis for believing the limitation can be evaluated without a new search and with only nominal further consideration; identifying an amendment for discussion does not overcome the substantive restrictions on after-final interviews. A general request to discuss “patentability” gives the examiner much less reason to expect progress. Submitted agendas and proposed amendments also become part of the record, so tentative language deserves the same care as other prosecution communications (USPTO, AIPLA & IPO, Interview Best Practices 2–4, 7–8 (May 2026); 37 C.F.R. § 1.2; MPEP §§ 713.01, 713.04, 713.09). The Best Practices document provides recommendations; compliance does not replace the governing rules.
Interview timing must also be coordinated with pre-appeal review. No interview is granted between filing a pre-appeal review request and issuance of the decision on that request. After an appeal brief is filed, interviews are generally unavailable except in unusual circumstances. Counsel contemplating both an interview and pre-appeal review should ordinarily pursue the interview first, without allowing the response deadline to expire (MPEP §§ 1204.02–1204.03, 713.05).
Chinese examiner meetings and telephone discussions likewise serve to clarify and resolve issues, but the procedural stage controls their role. After a rejection decision, the applicant must use the reexamination route to challenge the refusal; contacting the original examiner does not replace that filing. Reexamination itself may involve written consideration, an oral hearing, or both. U.S. counsel should therefore request communication appropriate to the Chinese proceeding rather than assume that the USPTO’s informal after-final pattern or time-credit policy applies there (CNIPA Guidelines pt. II, ch. 8, §§ 4.12–4.13, 6; pt. IV, ch. 2, § 4.3; Chinese Patent Law art. 41).
Obtaining further examination through an RCE
An RCE is useful when the U.S. applicant needs further examination in the existing application. With the required submission and fee in an eligible case, it provides a route for considering amendments, evidence, or arguments after prosecution has closed. It does not initiate a new application or establish a new filing date. Nor must the applicant first prove that the examiner’s rejection was erroneous. The applicant may simply conclude that another examination round is worth the expense (35 U.S.C. § 132(b); 37 C.F.R. § 1.114; MPEP § 706.07(h); USPTO, Request for Continued Examination Transmittal, PTO/SB/30, and instructions).
An RCE nevertheless has limits. It does not guarantee another nonfinal action, and it does not establish a right to switch to an independent and distinct invention. Those limits matter when counsel expects the RCE to accommodate claims driven by a new commercial objective. A continuing application may be the better vehicle for a different claim strategy, while the RCE addresses continued examination of the pending case (37 C.F.R. §§ 1.114, 1.145; MPEP §§ 706.07(b), 706.07(h), pt. VI).
China has no general request-and-fee procedure that duplicates this combination of features. After rejection, a supported, defect-directed amendment can be pursued within reexamination. That route may lead to withdrawal of the rejection and further processing, but its organizing principle remains review and correction of the refusal. Instructions to “file the Chinese equivalent of an RCE” conceal the questions that matter: which defect is being addressed, what amendment is permitted, and why the rejection should no longer stand.
The closure of AFCP 2.0 also belongs in current U.S. strategy. Requests under that program had to be filed by December 14, 2024. Its former additional consideration mechanism should not appear in a current list of available alternatives. Ordinary Rule 1.116 practice remains relevant, but counsel should assess its prospects under the present rules and examination policies (USPTO, After Final Consideration Pilot Program 2.0—CLOSED).
Using pre-appeal brief review to test the existing rejection
The document often called a “pre-appeal brief” is the argument accompanying a Pre-Appeal Brief Request for Review. The procedure allows an applicant to seek focused internal review before investing in a full appeal brief. It is best suited to a clear legal or factual deficiency in the rejection, such as the absence of support for a required claim limitation. Substantial disputes about claim interpretation or what a reference teaches may require the fuller treatment available on appeal. The request concerns appealable issues; it is not a substitute for a petition challenging finality (USPTO, New Pre-Appeal Brief Conference Pilot Program, 1296 Official Gazette 67 (July 12, 2005); MPEP § 1204.02).
The request must accompany a timely notice of appeal and precede the appeal brief. Its five-page limit excludes Form PTO/AIA/33. The notice-of-appeal fee is required, but there is no additional pre-appeal review fee. Counsel cannot file the notice first and add the request later through an extension. An after-final amendment filed on the same day makes the request noncompliant, even when submitted separately. That restriction deserves particular attention from Chinese practitioners accustomed to coupling review arguments with a corrective amendment (MPEP § 1204.02; USPTO, Pre-Appeal Brief Request for Review, PTO/AIA/33 (rev. Nov. 2023)).
A focused request can be organized around a short chain of propositions. Identify the disputed claim language, state the examiner’s material finding, cite the portion of the record that contradicts or fails to support it, and explain why the deficiency matters to the rejection. For example, if the existing claim already requires invalidation of a credential after one use but the cited passage describes a credential that remains reusable, counsel can identify that omission directly. A five-page discussion of the invention’s general advantages would obscure the issue. The actual rejection must still be addressed: identifying an omission in one reference will not suffice if the examiner relies on another reference or a separately articulated combination to supply the feature.
The applicant does not attend the review conference. Its possible results are continued appeal, reopening of prosecution, allowance on the existing claims, or dismissal of a noncompliant request. Dismissal of the request does not, by itself, dismiss an otherwise valid appeal. Counsel must preserve the appeal-brief deadline; a noncompliant request cannot be corrected and resubmitted later to cure the defect, because it would no longer accompany the notice of appeal. A decision that an issue remains for appeal is not a Board determination that the rejection is correct. If a brief remains necessary, its deadline becomes the later of one month from mailing of the panel decision or the balance of the original two-month brief period, subject to available extensions (MPEP § 1204.02; New Pre-Appeal Brief Conference Pilot Program, 1296 Official Gazette 67 (July 12, 2005)). Section 1204.02 addresses noncompliant requests, later resubmission, conference outcomes, and the appeal-brief period.
The request also commits the applicant to a particular sequence while review is pending. Filing an appeal brief, RCE, after-final amendment, affidavit or other evidence, or express abandonment before the panel decision ends the review. Coupled with the interview restriction, this makes pre-appeal review a deliberate choice to test the existing rejection. It should not be filed as a placeholder while counsel simultaneously attempts to negotiate a new claim set (MPEP §§ 1204.02–1204.03).
Chinese interlocutory examination, or qianzhi shencha, supplies the closest teaching comparison for this early reconsideration function. Following formal acceptance, the reexamination materials are forwarded to the examination department for its opinion. The department may agree that the rejection should be withdrawn because the request is persuasive or because permissible amendments cure the defects. A favorable interlocutory opinion is followed by a formal reexamination decision from the Reexamination and Invalidation Department under Section 3.3(5). The examination department may resume the approval procedure only after that decision. This is a stage of Chinese reexamination, rather than a separate five-page option that the applicant elects alongside a notice of appeal (CNIPA Guidelines pt. IV, ch. 2, §§ 3.1–3.3, especially § 3.3(5); CNIPA, Explanation of the 2023 Guidelines Amendments, Part Six, item 4 (Jan. 18, 2024)). The current Guidelines refer to the examination department, not necessarily the same individual examiner.
The analogy is useful because both processes can avoid unnecessary progression to a later review stage. Its limit is equally useful: Chinese counsel may seek reconsideration of an amended application within the permitted reexamination framework, whereas a U.S. pre-appeal request is directed to the rejection on the existing record. U.S. counsel should therefore prepare a substantive Chinese reexamination request that presents the desired argument and permissible fallback; Chinese counsel should resist importing that amendment practice into a U.S. pre-appeal filing.
A September 2026 USPTO notice adds another distinction. An administrative patent judge may serve as a third conferee in pre-appeal and appeal conferences, but acts in an advisory capacity. That judge cannot later sit on the PTAB merits panel for the application. Participation by a judge thus does not convert the conference into a Board decision or give the applicant a right to present oral argument at it (USPTO, Update to Panels for Pre-Appeal and Appeal Conferences 1–2 (Sept. 10, 2026)). The notice permits participation and does not require an APJ in every conference.
Proceeding through merits review and responding to new issues
A U.S. applicant may appeal once at least one claim meets the statutory twice-rejected condition; a final rejection is not the only possible trigger. The notice of appeal initiates the process, and the appeal brief ordinarily follows within two months, subject to applicable extensions and the pre-appeal procedure described above. The brief must address the grounds the applicant seeks to overturn. When dependent claims deserve separate treatment, counsel must develop the corresponding arguments rather than assume that their additional limitations will be considered independently (35 U.S.C. § 134(a); 37 C.F.R. §§ 41.31, 41.37; MPEP §§ 1204, 1205.01–1205.02).
The examiner’s answer, any reply brief, payment of the appeal forwarding fee, and any requested oral hearing are distinct subsequent steps. Internal appeal conferences and the Board’s adjudication also perform different functions. The resulting record should make clear what claims are at issue, why the examiner’s reasoning is challenged, and which separately argued claims provide alternative grounds for relief. An applicant who needs a substantially different claim or new proof should consider whether the case is ready for appellate review at all (37 C.F.R. §§ 41.39, 41.41, 41.45, 41.47; MPEP §§ 1207–1209). The appeal forwarding fee is addressed in § 41.45 and MPEP § 1208.01.
Chinese reexamination proceeds through formal review, interlocutory examination, and panel consideration where required. The reviewing body is the CNIPA Patent Office’s Reexamination and Invalidation Department; references to the former Patent Reexamination Board can obscure the current institutional structure. The panel generally addresses the refusal’s grounds and evidence, but it may consider specified additional defects, including certain obvious substantive defects. Reexamination is therefore a continuation of the approval process as well as a remedy against refusal (Implementing Regulations r. 67; CNIPA Guidelines pt. IV, ch. 2, §§ 1, 4.1; CNIPA, Explanation of the 2023 Guidelines Amendments, Part Six, items 1, 5 (Jan. 18, 2024)).
That continuing examination function does not eliminate the applicant’s opportunity to respond. The Guidelines provide for notice or oral proceedings when an adverse decision is contemplated, amendments or additional explanations are needed, or new grounds or evidence are introduced. A written reexamination notice ordinarily requires a substantive written response within one month of receipt; failure to respond can cause the request to be treated as withdrawn. Counsel should docket that later response obligation separately from the three-month period for initiating reexamination (Implementing Regulations r. 67; CNIPA Guidelines pt. IV, ch. 2, § 4.3). An oral-hearing notice has its own response and attendance provisions.
U.S. appeal practice requires attention to both the source of a new ground and the sequence of filings. When an examiner’s answer designates a new ground, Rule 41.39(b) gives the applicant two months from the answer’s date to choose between reopening prosecution and maintaining the appeal. Reopening under Rule 41.39(b)(1) requires a Rule 1.111 reply, with or without amendment or evidence; any amendment or evidence must relate to the new ground. Maintaining the appeal instead requires a reply brief addressing the new ground, without an accompanying amendment or evidence (37 C.F.R. § 41.39(b)–(c); MPEP § 1207.03(c)). Under § 41.39(b)(2), a reply brief accompanied by an amendment or evidence is treated as a request to reopen prosecution.
An applicant seeking review of the examiner’s failure to designate a new ground of rejection must use the petition procedure under Rules 1.181 and 41.40. An applicant seeking only to answer newly presented examiner arguments on the existing record may instead respond in a reply brief, subject to the rules governing that brief. The petition must be filed within two months from entry of the examiner’s answer and before any reply brief. Under Rule 41.40(d), filing a reply brief within two months from the answer’s date while the petition remains undecided is treated as withdrawing the petition and maintaining the appeal. The petition tolls the reply-brief period; the decision on it specifies the next response period and filing. Counsel therefore must sequence the petition and reply brief rather than treat them as independent filings that can safely proceed simultaneously (37 C.F.R. §§ 1.181, 41.40(a)–(e), 41.41(b)(2); MPEP § 1207.03(b) (discussing In re Durance, 891 F.3d 991, 998 (Fed. Cir. 2018))). Grant of the petition supplies two months to file a Rule 1.111 reply to reopen prosecution; denial supplies two months in which to file a single reply brief. Section 41.40(d) specifies the timing conditions under which a reply brief withdraws the petition.
A Board-designated new ground under Rule 41.50(b) requires a different choice within two months from the Board’s decision. Reopening under Rule 41.50(b)(1) calls for an appropriate amendment of the rejected claims, new evidence relating to those claims, or both. The alternative is rehearing on the existing record under Rule 41.50(b)(2). An argument-only response that can support reopening after an examiner-designated new ground thus does not meet the Board-reopening requirements. An alleged undesignated new ground in the Board’s decision must instead be raised through a timely request for rehearing under Rules 41.50(c) and 41.52, rather than the examiner-answer petition procedure. Ordinary Rule 1.136(a) extensions are unavailable for the periods under Rules 41.39, 41.40, and 41.50; counsel must docket them separately from the ordinary after-final response period (37 C.F.R. §§ 41.39(c), 41.40(e), 41.50(b)–(c), (f), 41.52; MPEP §§ 1207.03, 1213). Under § 41.50(c), failure to raise the Board’s alleged failure to designate a new ground in a timely rehearing request waives the designation argument. The rules refer patent applicants to § 1.136(b) for separately requested extensions; the automatic fee-extension provisions of § 1.136(a) do not apply.
Success at either office must also be described accurately to the client. Removing the disputed rejection may lead to further processing or examination. It does not invariably mean that the patent will issue immediately. Chinese practitioners should distinguish U.S. reopening from Board reversal, and U.S. practitioners should distinguish withdrawal of the Chinese refusal from a completed grant. In China, resumed examination must implement the reexamination decision: Part IV, Chapter 2, Section 7 prohibits a contrary decision based on the same facts, reasons, and evidence. A favorable decision therefore constrains further examination even though it does not itself grant a patent (CNIPA Guidelines pt. IV, ch. 2, § 7). When the rejection decision is revoked, the file returns to the examination department, which must implement the reexamination decision and may not reach a contrary decision on the same facts, reasons, and evidence.
Preserving other claim coverage in a separate application
A U.S. continuation or divisional creates a separate application in which supported claims can be pursued, subject to the applicable benefit and copendency requirements. An RCE instead continues the existing application. The distinction becomes commercially important when the client wants both to contest the rejection of the current claims and to pursue a different supported claim set. A child application can preserve another route, but its filing does not itself answer the parent’s Office action or stop the parent’s deadline (35 U.S.C. §§ 120–121; 37 C.F.R. § 1.78; MPEP §§ 201.06–201.07).
Chinese divisionals also permit separate pursuit of subject matter, but their filing windows must be examined under Chinese rules. Following a rejection decision, a divisional may be filed within three months of receipt even if no reexamination request is made. Additional windows include the pending reexamination period, the three months following receipt of the reexamination decision, and administrative litigation challenging that decision. These opportunities do not make every new claim permissible, and the original-disclosure and other substantive requirements continue to apply (CNIPA Guidelines pt. I, ch. 1, § 5.1.1; Chinese Patent Law art. 33; CNIPA Customer Service Center, Response to “Whether a Divisional Application May Be Filed When the Unity Requirement Is Satisfied” (Dec. 12, 2025) (public consultation response; title translated from Chinese)).
Further divisionals create a particular trap for U.S. counsel. Chinese timing generally remains tied to the original application, with a specified exception for a further divisional responding to an examiner-raised unity defect in a divisional. A still-pending child therefore should not automatically be treated as supporting the same continuation-chain strategy familiar in U.S. practice. When the business changes direction, instructions should identify the desired claims and ask which Chinese filing window actually supports them (CNIPA Guidelines pt. I, ch. 1, § 5.1.1; CNIPA Customer Service Center, Response to “Whether a Divisional Application May Be Filed When the Unity Requirement Is Satisfied” (Dec. 12, 2025) (public consultation response; title translated from Chinese)).
Placing judicial review after the correct agency decision
A merits disagreement with a U.S. examiner ordinarily reaches court after PTAB review. Following the relevant adverse Board decision, a patent applicant may seek Federal Circuit review under Section 141 or pursue the alternative civil action under Section 145, subject to the applicable election and timing rules. The examiner’s final action and the Board’s appeal decision occupy different places in that sequence. Under Rule 90.3, the ordinary deadline for filing the notice of appeal or commencing the civil action is 63 days after the date of the final Board decision. A timely rehearing request ordinarily resets the period to 63 days after action on that request (35 U.S.C. §§ 141(a), 145; 37 C.F.R. §§ 90.1–90.3, especially § 90.3(a)(1), (a)(3)(i), (b)(1)–(2), (c); MPEP § 1216). A subsequent rehearing request by the same party does not reset the period unless permitted by Board order. The rule also addresses holiday computation and extensions requested on good cause before expiration or excusable neglect afterward. These applicant-review routes should not be generalized to every post-grant proceeding.
In China, Article 41 permits an applicant dissatisfied with the reexamination decision to bring a court action within three months of receipt. The Chinese period thus runs from receipt, while the ordinary U.S. period runs from the decision’s date. The initial rejection, the agency’s reexamination decision, and the court’s judgment must therefore be distinguished in reporting and instructions. Correspondence asking counsel simply to “appeal” should identify both the decision being challenged and the forum sought (Chinese Patent Law art. 41, para. 2).
Applying the comparison to four recurring client problems
A supported fallback needs examination
Return to the controller and single-use credential. If the rejected claim lacks the single-use limitation, the U.S. decision turns partly on whether the examiner can enter and evaluate that change after final. If further examination is needed, an RCE may provide the appropriate route. In China, counsel should evaluate a defect-directed amendment within reexamination. The same technical proposal therefore requires separate instructions about support, admissibility, and the requested procedural relief.
The existing rejection overlooks a limitation
If the claim already contains the limitation and the examiner’s rejection does not account for it, the commercial objective may be to preserve the existing scope. A focused U.S. pre-appeal request can test a demonstrable error before full briefing. A Chinese reexamination request can present the corresponding defect in the refusal. Narrowing reflexively in both jurisdictions would confuse the need to correct the decision with the need to change the invention being claimed.
Counsel wants another interview
If an earlier U.S. interview has already used the ordinary time allocation, counsel should explain why an additional discussion warrants examiner preparation and, where needed, approval for more time. The substantive after-final standard still matters. Once a pre-appeal request is pending, however, the interview restriction controls. For the corresponding Chinese case, the first question is whether ordinary examination remains open or a rejection decision requires reexamination. The request for a conversation follows from that answer.
The client wants a different commercial embodiment
If the new objective concerns a different supported embodiment or claim category, neither an appeal brief nor a reexamination amendment should be assumed to accommodate the change. U.S. continuation practice and Chinese divisional practice deserve separate analysis. Counsel should protect the filing opportunity for the new claim strategy while deciding independently whether continued pursuit of the parent claims justifies the expense.
Giving instructions that preserve the intended result
U.S. attorneys directing Chinese prosecution should identify the rejection decision and service date, explain the error or propose a permitted corrective amendment, and ask whether divisional coverage should be preserved. The reexamination request must present the substantive case for relief within the disclosure and amendment limits.
Chinese attorneys directing U.S. prosecution should identify the live deadline, entered claims, and available evidence, then select and sequence the procedures that serve the client’s objective. A limited after-final submission, interview, RCE, pre-appeal request, full appeal, and continuing application each performs a different function. Effective cross-border instructions preserve the commercial objective while translating the requested action into the receiving office’s procedure.
